AR011728A1 - FORMULACIoN FARMACÉUTICA DE GRÁNUKOS ENTÉRICOS DE FLUOXETINA Y SU USO PARA PREPARAR UN MEDICAMENTO. - Google Patents

FORMULACIoN FARMACÉUTICA DE GRÁNUKOS ENTÉRICOS DE FLUOXETINA Y SU USO PARA PREPARAR UN MEDICAMENTO.

Info

Publication number
AR011728A1
AR011728A1 ARP980102130A ARP980102130A AR011728A1 AR 011728 A1 AR011728 A1 AR 011728A1 AR P980102130 A ARP980102130 A AR P980102130A AR P980102130 A ARP980102130 A AR P980102130A AR 011728 A1 AR011728 A1 AR 011728A1
Authority
AR
Argentina
Prior art keywords
granukos
fluoxetine
enteral
prepare
pharmaceutical formulation
Prior art date
Application number
ARP980102130A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011728(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR011728A1 publication Critical patent/AR011728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una formulacion entérica superior de un fármaco antidepresivo, floxetina, que está en forma de gránulos entéricos en los que la capa entérica comprendesuccinato acetato de hidropropilmetilcelulosa.
ARP980102130A 1997-05-29 1998-05-07 FORMULACIoN FARMACÉUTICA DE GRÁNUKOS ENTÉRICOS DE FLUOXETINA Y SU USO PARA PREPARAR UN MEDICAMENTO. AR011728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (1)

Publication Number Publication Date
AR011728A1 true AR011728A1 (es) 2000-08-30

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102130A AR011728A1 (es) 1997-05-29 1998-05-07 FORMULACIoN FARMACÉUTICA DE GRÁNUKOS ENTÉRICOS DE FLUOXETINA Y SU USO PARA PREPARAR UN MEDICAMENTO.

Country Status (46)

Country Link
US (3) US5910319A (es)
JP (1) JP3210288B2 (es)
KR (1) KR100549473B1 (es)
CN (2) CN1161109C (es)
AR (1) AR011728A1 (es)
AT (1) AT408068B (es)
AU (1) AU726690B2 (es)
BE (1) BE1011925A3 (es)
BR (1) BR9801989A (es)
CA (1) CA2234826C (es)
CH (1) CH693018A5 (es)
CO (1) CO4940407A1 (es)
CZ (1) CZ290582B6 (es)
DE (1) DE19823940B4 (es)
DK (1) DK176776B1 (es)
ES (1) ES2161574B1 (es)
FI (1) FI119971B (es)
FR (1) FR2763846B1 (es)
GB (1) GB2325623B (es)
GR (1) GR980100188A (es)
HK (1) HK1034902A1 (es)
HU (1) HUP9800882A3 (es)
ID (1) ID20343A (es)
IL (1) IL124073A (es)
IT (1) ITMI980908A1 (es)
LT (1) LT4477B (es)
LU (1) LU90245B1 (es)
LV (1) LV12176B (es)
MY (1) MY118139A (es)
NL (1) NL1009259C2 (es)
NO (1) NO317743B1 (es)
NZ (1) NZ330192A (es)
PE (1) PE75399A1 (es)
PL (1) PL192293B1 (es)
PT (1) PT102152B (es)
RO (1) RO120043B1 (es)
RS (1) RS49827B (es)
RU (1) RU2164405C2 (es)
SE (1) SE522914C2 (es)
SG (1) SG72805A1 (es)
SI (1) SI9800128B (es)
SV (1) SV1998000052A (es)
TR (1) TR199800937A3 (es)
TW (1) TWI239838B (es)
UA (1) UA48193C2 (es)
ZA (1) ZA983173B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
RU2275191C2 (ru) * 1999-05-20 2006-04-27 Элан Корпорейшн, Плс Состоящие из множества частиц фармацевтические составы с контролируемым высвобождением избирательного ингибитора повторного поглощения серотонина
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
DE60026146T2 (de) * 1999-09-03 2006-08-17 Apbi Holdings, Llc Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
AU2002212102A1 (en) * 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004058228A1 (en) * 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
CA2753318A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
WO2005105045A1 (ja) * 2004-04-30 2005-11-10 Astellas Pharma Inc. 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007067581A1 (en) * 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
BRPI0708191A2 (pt) * 2006-02-24 2012-05-29 Teva Pharma " composições farmacêuticas de fluvastatina sódica "
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
BRPI0711606A2 (pt) * 2006-05-22 2012-02-14 Teva Pharma formulações de hidrocloreto de duloxetina de liberação retardada
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
BRPI0714915A2 (pt) * 2006-07-28 2013-05-28 Reddys Lab Ltd Dr composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
BRPI0916241A2 (pt) 2008-07-16 2017-06-27 Richter Gedeon Nyrt formulações farmacêuticas contendo ligantes de receptores de dopamina
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
US20120207825A1 (en) * 2009-09-17 2012-08-16 Sunilendu Bhushan Roy Pharmaceutical compositions for reducing alcohol-induced dose dumping
EP2540318B1 (en) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
US10525010B2 (en) 2012-05-02 2020-01-07 Capsugel Belgium Nv Aqueous dispersions of controlled release polymers and shells and capsules thereof
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
TWI566786B (zh) 2012-09-03 2017-01-21 第一三共股份有限公司 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN106456555B (zh) * 2014-05-20 2019-05-07 陶氏环球技术有限责任公司 包含酯化纤维素醚的胶囊壳
US10179110B2 (en) 2014-05-20 2019-01-15 Dow Global Technologies Llc Dispersion comprising a partially neutralized esterified cellulose ether
US10564114B2 (en) * 2014-06-07 2020-02-18 Structure-Ase Incorporated Method for the detection and/or diagnosis of eating disorders and malnutrition using X-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CA3096453A1 (en) 2017-04-13 2018-10-18 Chase Therapeutics Corporation Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
AU1429092A (en) * 1991-02-04 1992-09-07 Timothy J Barberich Methods of use and compositions of r(-) fluoxetine
HUT69390A (en) * 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
ES2124303T3 (es) * 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
CA2175494C (en) * 1993-11-03 2000-09-19 Young W. Cho Microparticular pharmaceutical compositions
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
FI980846A (fi) 1998-11-30
CA2234826A1 (en) 1998-11-29
AT408068B (de) 2001-08-27
DE19823940A1 (de) 1998-12-03
LU90245A1 (es) 1998-11-30
IE980284A1 (en) 2000-07-12
ES2161574B1 (es) 2002-06-16
PT102152B (pt) 2000-09-29
CN1212834C (zh) 2005-08-03
NO982197D0 (no) 1998-05-14
AU726690B2 (en) 2000-11-16
LT4477B (lt) 1999-03-25
GB9807939D0 (en) 1998-06-10
TWI239838B (en) 2005-09-21
GB2325623B (en) 1999-04-14
LT98058A (en) 1998-10-26
TR199800937A2 (xx) 1999-10-21
ATA93198A (de) 2001-01-15
JPH10330253A (ja) 1998-12-15
CN1161109C (zh) 2004-08-11
TR199800937A3 (tr) 1999-10-21
IL124073A (en) 2002-02-10
UA48193C2 (uk) 2002-08-15
ID20343A (id) 1998-12-03
FI980846A0 (fi) 1998-04-16
CH693018A5 (de) 2003-01-31
RU2164405C2 (ru) 2001-03-27
BR9801989A (pt) 2000-02-08
PL326134A1 (en) 1998-12-07
JP3210288B2 (ja) 2001-09-17
KR19980086622A (ko) 1998-12-05
HU9800882D0 (en) 1998-05-28
SI9800128A (sl) 1999-02-28
DE19823940B4 (de) 2010-04-29
DK176776B1 (da) 2009-08-10
CN1285189A (zh) 2001-02-28
FI119971B (fi) 2009-05-29
LV12176B (en) 1999-03-20
LU90245B1 (fr) 2002-07-31
SV1998000052A (es) 1999-03-16
KR100549473B1 (ko) 2006-03-23
SE522914C2 (sv) 2004-03-16
PL192293B1 (pl) 2006-09-29
CZ290582B6 (cs) 2002-08-14
ITMI980908A1 (it) 1999-10-28
FR2763846B1 (fr) 2001-05-18
US5910319A (en) 1999-06-08
MY118139A (en) 2004-09-30
GR980100188A (el) 1999-01-29
NZ330192A (en) 1999-08-30
HK1034902A1 (en) 2001-11-09
PT102152A (pt) 1998-12-31
NO982197L (no) 1998-11-30
SE9801336D0 (sv) 1998-04-17
YU16598A (en) 1999-11-22
NL1009259C2 (nl) 1998-12-01
SG72805A1 (en) 2000-05-23
CZ114398A3 (cs) 1998-12-16
CO4940407A1 (es) 2000-07-24
CA2234826C (en) 2000-12-19
SI9800128B (sl) 2000-04-30
USRE39030E1 (en) 2006-03-21
NO317743B1 (no) 2004-12-13
RO120043B1 (ro) 2005-08-30
ES2161574A1 (es) 2001-12-01
HUP9800882A3 (en) 2000-07-28
LV12176A (lv) 1998-12-20
BE1011925A3 (fr) 2000-03-07
HUP9800882A2 (hu) 2000-03-28
PE75399A1 (es) 1999-08-17
SE9801336L (sv) 1998-11-30
ZA983173B (en) 1999-10-15
US5985322A (en) 1999-11-16
AU6904898A (en) 1998-12-03
FR2763846A1 (fr) 1998-12-04
RS49827B (sr) 2008-08-07
GB2325623A (en) 1998-12-02
CN1200924A (zh) 1998-12-09

Similar Documents

Publication Publication Date Title
AR011728A1 (es) FORMULACIoN FARMACÉUTICA DE GRÁNUKOS ENTÉRICOS DE FLUOXETINA Y SU USO PARA PREPARAR UN MEDICAMENTO.
AR008462A1 (es) COMPOSICIoN FARMACÉUTICA QUE COMPRENDE OLANZAPINA Y CLORHIDRATO DE FLUOXETINA Y USO DE DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO.
ES2157297T3 (es) Granulos entericos de duloxetina.
AR012927A1 (es) Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial
MX9202118A (es) Formulacion de tableta que tiene una estructura que comprende granulos compactados de una mezcla de medicamento y un desintegrante inter-granular y proceso para su fabricacion.
AR017205A1 (es) ANILIDAS MIMÉTICAS DE ÁCIDO RETINOICO, PROCESOS PARA PREPARAR DICHOS COMPUESTOS, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, UN PROCESO PARA PREPARAR DICHAS COMPOSICIONES Y EL USO DE DICHOS COMPUESTOS EN LA ELABORACIoN DE MEDICAMENTOS.
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
BR9711328A (pt) 7Alfa-(epsilon-aminoalquil)-estratrienos processos para a sua prepara-Æo preparados farmaceuticos que contem estes 7 alfa-(epsilon-aminoalquil)- estratrienos bem como seu emprego para a prepara-Æo de medicamentos
AR011709A1 (es) Un sistema de aplicacion de drogas, de preferencia con forma de anillo, adecuado para la administracion vaginal
DE69721559D1 (de) Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
AR002982A1 (es) Benzonitrilos y benzofluoruros, un procedimiento para prepararlos, su empleo para preparar médicamentos, un médicamento hecho a base de estos compuestos, las preparaciónes farmacéuticas que los contienen y un procedimiento para obtener estas preparaciónes farmacéuticas.
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
EE200100037A (et) Bensotsüklohepteenid, nende valmistamise meetod, neid sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
ATE287699T1 (de) Pharmazeutische aerosolzusammensetzungen
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
AR010399A1 (es) DERIVADOS DE AMIDAS DE LOS ÁCIDOS ISOXAZoLICO Y CROToNICO , PROCEDIMIENTO PARA SU PREPARACIoN MEDICAMENTO QUE LOS CONTIENE Y SU UTILIZACIoN COMO MEDICAMENTOS Y COMO AGENTES DE DIAGNoSTICO
AR028023A1 (es) Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos
AR028588A1 (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y uso
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
AR017884A1 (es) Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion
DE69813624D1 (de) Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
AR011707A1 (es) Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento.

Legal Events

Date Code Title Description
FC Refusal